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Abstract
The seven antigenically distinct serotypes of Clostridium botulinum neurotoxins, the causative agents of botulism, block the
neurotransmitter release by specifically cleaving one of the three SNARE proteins and induce flaccid paralysis. The Centers
for Disease Control and Prevention (CDC) has declared them as Category A biowarfare agents. The most potent among
them, botulinum neurotoxin type A (BoNT/A), cleaves its substrate synaptosome-associated protein of 25 kDa (SNAP-25). An
efficient drug for botulism can be developed only with the knowledge of interactions between the substrate and enzyme at
the active site. Here, we report the crystal structures of the catalytic domain of BoNT/A with its uncleavable SNAP-25
peptide
197QRATKM
202 and its variant
197RRATKM
202 to 1.5 A ˚ and 1.6 A ˚, respectively. This is the first time the structure of an
uncleavable substrate bound to an active botulinum neurotoxin is reported and it has helped in unequivocally defining S1
to S59 sites. These substrate peptides make interactions with the enzyme predominantly by the residues from 160, 200, 250
and 370 loops. Most notably, the amino nitrogen and carbonyl oxygen of P1 residue (Gln197) chelate the zinc ion and
replace the nucleophilic water. The P19-Arg198, occupies the S19 site formed by Arg363, Thr220, Asp370, Thr215, Ile161,
Phe163 and Phe194. The S29 subsite is formed by Arg363, Asn368 and Asp370, while S39 subsite is formed by Tyr251,
Leu256, Val258, Tyr366, Phe369 and Asn388. P49-Lys201 makes hydrogen bond with Gln162. P59-Met202 binds in the
hydrophobic pocket formed by the residues from the 250 and 200 loop. Knowledge of interactions between the enzyme
and substrate peptide from these complex structures should form the basis for design of potent inhibitors for this
neurotoxin.
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Introduction
Clostridium botulinum neurotoxins (CNTs) are the most potent
toxins known to humans since even one billionth of an ounce is
fatal. Seven antigenically distinct botulinum neurotoxins are
produced by the bacterium Clostridium botulinum and they share
considerable sequence homology, and structural and functional
similarity [1–3]. They are produced as inactive single chains of
molecular mass 150 kDa and released as active dichains, a heavy
chain (HC, 100 kDa) and a light chain (LC, 50 kDa) held together
by an interchain disulfide bond [4–7]. HC comprising two distinct
domains is responsible for binding to neuronal cells and
translocation into cytosol. LC is the catalytic domain cleaving
one of the three proteins forming the SNARE complex (Soluble N-
ethylmaleimide-sensitive fusion protein attachment protein recep-
tors) required for docking and fusion of vesicles containing
neurotransmitters to target cells [8–12]. The SNARE complex
formation is prevented when any of the SNARE proteins is
cleaved and accordingly blocks neurotransmitter release leading to
flaccid paralysis and eventual death.
Catalytic domains of BoNTs are zinc proteases and cleave
SNARE proteins with stringent substrate specificity though they
share significant sequence similarity. BoNT/A and BoNT/E
cleave the synaptosomal-associated 25 kDa protein (SNAP-25)
while BoNT/B, /D, /F, and /G cleave the vesicle-associated
membrane protein (VAMP). BoNT/C is the only one that has
dual substrate specificity, viz SNAP-25 and syntaxin [13]. The
enhanced substrate specificity of CNTs is due to the recognition of
substrates at remote sites called exosites in addition to the active
site [14].
The potency and the ease with which these toxins can be
produced make them potential bioweapons and bioterrorism
agents. The Centers for Disease Control and Prevention (CDC)
has declared them as Category A biowarfare agents. Currently,
while experimental vaccines are available, only an equine trivalent
antitoxin is available for post-exposure therapeutics with a limited
therapeutic window [15]. One of the most effective ways a drug
can act is by blocking the site where the substrate binds to toxin
and accordingly the crystal structure of substrate-enzyme complex
is essential to map out a strategy. Even though crystal structure of
SNAP peptide (146–206)-inactive enzyme complex is available, it
lacks interactions at the active site since the enzyme used was an
inactive double mutant [14]. Here we present for the first time the
structure of the substrate peptide, QRATKM containing the
scissile peptide bond, bound to the active enzyme. This crystal
structure reveals interesting features of complex formation which
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botulism. It is remarkable that this natural substrate peptide is not
cleaved by the enzyme. In addition, we are also reporting the
crystal structure of RRATKM, a variant of the substrate peptide,
in complex with the enzyme. Though both are weak inhibitors,
RRATKM is a better inhibitor than QRATKM.
Materials and Methods
Protein expression and purification
Clostridium botulinum neurotoxin serotype A truncated light chain
(residues 1 to 424), Balc424, was expressed in E. coli and purified to
homogeneity using size exclusion chromatography, as described
previously [16]. The purified enzyme in 20 mM HEPES, 2 mM
DTT, 200 mM NaCl, pH 7.4 was stored at 220uC until used.
Amides of the peptides, QRATKM and RRATKM, were custom
synthesized by Peptide 2.0 Inc., Chantilly, VA20153, USA. The
stock solutions of the peptides were prepared with the above
mentioned buffer.
Crystallization and data collection
Balc424-QRATKM and Balc424-RRATKM complex crystals
were grown using a range of protein/peptide molar ratio (1:5 to
1:30). Both QRATKM and RRATKM complex crystals were
grown by sitting drop vapor diffusion at room temperature.
Briefly, 3 ml of the protein solution (15 mg/ml) was mixed with an
equal volume of a reservoir solution containing 20% PEG 8000,
100 mM sodium cacodylate, pH 6.5, 5% ethylene glycol and 200
mM ammonium sulfate. Thick plate-like crystals were obtained in
five days and were flash frozen with liquid nitrogen using 20%
ethylene glycol as cryoprotectant. The X-ray intensity data for
both complex crystals were collected at X29 beamline of National
Synchrotron Light Source (NSLS) using ADSC QUANTUM 315
detector. Balc424-QRATKM and Balc424-RRATKM complex
crystals diffracted to 1.5 A ˚ and 1.6 A ˚, respectively and belonged to
the P21 space group with one molecule in the asymmetric unit
(Table 1). All data were processed using the HKL2000 suite [17].
Structure determination
The structures of the complexes were determined by Fourier
Synthesis using the acetate bound Balc424 (Protein Data Bank id
3BWI) as model followed by rigid-body refinement and simulated
annealing. The composite omit map and the difference Fourier
showed interpretable electron density for these hexapeptides. The
best results were obtained with data collected from crystals grown
with 1:25 (protein/peptide) molar ratio. The peptide models were
built with O [18] and further refined with CNS [19] until
convergence. The final refinement statistics are shown in Table 1.
Models were validated with the Ramachandran plot using
PROCHECK [20].
Activity assay
The proteolytic activity of balc424 was determined by HPLC
using P[187–203] synthetic peptide as reported previously [21;
22]. Briefly, balc424 enzyme (550 nM) was incubated with the 17-
mer peptide (1mM) at 37uC for 30 min in the assay buffer (50 mM
Table 1. Crystal data and refinement statistics of Balc424
with substrate peptide complexes
Name/code QRATKM RRATKM
Cell dimensions a (A ˚) 49.14 50.87
b 66.20 66.58
c 64.82 65.06
b (u) 99.10 98.3
Space group P21 P21
Resolution range (A ˚) Overall 50–1.5 50–1.6
Last shell 1.54–1.50 1.65–1.6
# unique reflections 64,562 53,272
Completeness (%)
(Overall/Last shell) 97.4/80.0 95.4/76.3
Rmerge
1 overall/last shell 0.066/0.25 0.059/0.15
,I/s(I). overall/last shell 17/2.0 23.0/3.0
Refinement Statistics
Resolution (A ˚) 50–1.5 50–1.6
R factor
2/Rfree (%) 18.0/20.0 20.0/22.0
R.M.S deviation from
ideality
Bond lengths (A ˚) 0.005 0.005
Bond angles (u) 1.2 1.2
Average B-factors (A ˚2)
Main chain 14.0 21.1
Side chain 16.2 23.0
Waters 22.6 29.7
Ions 27.0 35.3












Residues (%) in the core
region of w-y plot 91.2 89.0





Botulinum neurotoxins are the most poisonous substance
to humans. The ease with which the bacteria can be
grown, its potency and persistence have made it a
potential bioterrorism agent, and accordingly, botulinum
neurotoxin has been declared as Category A agent by the
Centers of Disease Control and Prevention. Since it is both
a potential bioweapon and a bioterrorism agent, it is
imperative to develop counter measures and therapeutics
for these neurotoxins, as none are available so far except
experimental vaccines and an FDA-approved equine
antitoxin. Our work presented here is an important
milestone towards achieving this goal. The best antidote
can be developed by blocking the active site of any
enzyme. The crystal structures of substrate peptide–
enzyme complex presented here map the interactions
between the two and provide critical information for
designing effective drugs against this toxin.
Neurotoxin-Substrate Complex
PLoS Pathogens | www.plospathogens.org 2 September 2008 | Volume 4 | Issue 9 | e1000165HEPES, 0.25 mM ZnCl2, 5.0 mM DTT, pH 7.2). IC50 values
were determined by varying the concentration of inhibitors. The
experimental data were analyzed using equation 1, where I is the
inhibitor concentration, y is the percent inhibition, with a slope
factor (s) of 1.0.
y~100%=½1z(I=IC50)
s ð 1Þ
Coordinates and structure factors have been deposited to the
Protein Data Bank. BALC424-QRATKM (3DDA) and
BALC424-RRATKM (3DDB). The SwissProt accession number
for BoNT/A is P10845.
Results
Crystal structure of Balc424 with QRATKM
The crystal structure has been determined to 1.5A ˚ resolution.
The model refined with R and R free of 18.4 and 20.1%,
respectively. The final refined model contains 423 proteaseresidues,
6 substrate residues, one sulfate and one zinc ions and 375 waters.
More than 91% of residues are within the most allowed region of
the Ramachandran plot. The electron density in the residual map
(Fo-Fc) was well defined for the hexapeptide and QRATKM could
be modeled unambiguously except for the side chains of K and M
(Figure 1A). It appears that K could take two rotamer positions.
This is the first time an uncleavable substrate bound structure of an
active botulinum neurotoxin has been reported and it has helped in
unequivocally defining S1 to S59 sites. Most notably, the amino
nitrogen and carbonyl oxygen of P1 residue (Gln197) chelate the
zinc ion (Figures 2 and 3). The amino nitrogen has replaced the
nucleophilic water as was shown earlier [16].
Crystal structure of Balc424 with RRATKM
The crystal structure of Balc424 with a substrate analog
RRATKM has been determined to 1.6A ˚ resolution. The R and
R free for the final refined model are 20.1 and 21.2%, respectively.
The final refined model contains 423 residues of protease, 6
residues of substrate analog peptide, two sulfate ions, one zinc ion
and 375 waters. More than 90% of residues are within the most
allowed region of the Ramachandran plot. The substrate analog
could be modeled unambiguously in the residual map (Fo-Fc)
(Figure 1B). Except for some minor variations of side chain
orientations, the hexapetide RRATKM binds similar to the
substrate peptide QRATKM (Figures 2, 3 and 4). As in the case of
QRATKM, the P1 (Arg197) amino group and the carbonyl
oxygen chelate the catalytic zinc and the nucleophilic water has
been replaced. P1-P59 residues occupy identical subsites as in
QRATKM. This kind of interaction seems to be common with all
peptide analog inhibitors [16] and probably plays a dominant role
in inhibiting the catalytic activity.
Though we have shown earlier that short tetrapeptides (analogs
of substrate) are good inhibitors (nM range), the hexapeptides are
weak inhibitors [16]. The IC50 of QRATKM and RRATKM are
133 and 95 mM, respectively (Figures 1E and 1F).
Discussion
Mapping of S1–S59 subsites
The side chain of P1-Q197 is exposed to the solvent region but
makes a hydrogen bond with Glu164 OE1 (Figures 3 and 4).
However, it is stabilized by various other interactions as well. N
and O chelate zinc while O is also hydrogen bonded to Tyr366
OH which stabilizes the substrate and positions it for catalytic
activity. Mutation of Tyr366 to Phe or Ala resulted in dramatic
decrease in activity [23; 24]. The amino nitrogen which has
replaced the nucleophilic water is hydrogen bonded to Glu224
OE1 and OE2 (the latter through a water molecule). It is known
that variation in P1 does not affect the catalytic activity, probably
due to most of the interactions being with the main chain atoms
[25–28]. Mutation of Glu164 to Gln only had a marginal effect on
the catalytic activity [23]. The only difference between QRATKM
and RRATKM is at P1 residue. This was based on our previous
experience with tetrapeptides [16] since the positive charge on
Arg197 better complements the charge in the active site cavity.
While P1-Gln197 makes a hydrogen bond with Glu164, P1-
Arg197 makes a salt bridge interaction with Glu164 thus making it
more strongly bound (Figures 3 and 4). There are additional
Figure 1. Hexapeptides and inhibition plots. Electron density
maps (blue mesh) for bound substrate (QRATKM) and its variant
(RRATKM) are shown in A and B, respectively. The electron density is
from composite omit maps (2|Fo|-|Fc|) and contoured at 1s level.
QRATKM (green) and RRATKM (gray) peptides are shown in ball and
stick model. Zinc, oxygen and nitrogen atoms are shown as magenta,
red and blue spheres, respectively. Carbon atoms are shown in green
(QRATKM) and black (RRATKM). Figures were prepared using Molscript,
Raster3D and Bobscript [34–36]. Distribution of B factors for the
QRATKM and RRATKM are shown in C and D, respectively. The peptide
atoms are colored according to B factor with RGB (Red-Green-Blue)
color ramp with blue and red corresponding to the lowest (17 A ˚2) and
highest (50 A ˚2). Pymol (DeLano, W.L. The PyMOL Molecular Graphics
System (2002) on World Wide Web http://www.pymol.org) was used to
prepare C and D figures. Inhibition of Balc424 catalytic activity at
increasing concentrations (mM) of QRATKML (E) and of RRATKML (F).
doi:10.1371/journal.ppat.1000165.g001
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crystallization. Other than this, residues from 198 to 202 in both
structures superpose well except for minor variations in side chain
orientations (Figure 2B). The following discussion on subsites S19
to S59 applies equally for the both structures.
P19-Arg198 occupies the S19 site formed by Arg363, Thr220,
Asp370, Thr215, Ile161 and Phe194. Phe163, though slightly
farther, also forms part of this subsite. The amino nitrogen and
carbonyl oxygen of P19 are hydrogen bonded to Phe163 O and
Arg363 NH2 (Figures 3 and 4). These two interactions stabilize the
substrate binding. When Arg363 is mutated to Leu or Ala, the
activity decreases by 620 and ,80 fold, respectively [23; 24]. In
addition, the guanidinium group of P19 Arg198 forms salt bridges
with Asp370 and P19-Arg198 NE forms a hydrogen bond with
Ile161 O. The salt bridge interaction between P19-Arg198 and
Asp370 is crucial since mutation of Asp370 reduced the catalytic
activity by 250–600 fold [23; 29]. The other major interaction is
the stacking of guanidinium group of P19-Arg198 with Phe194
(Figure 3). This stacking interaction also plays a major role in the
activity since Balc424 Phe194Ala has ,100 fold less activity [29].
Accordingly, both the electrostatic and hydrophobic interactions
are crucial for catalytic activity. The S19 site is fairly big and gives
enough flexibility for Arg198. In substrate analog tetrapeptide
inhibitor complexes, it takes various rotamer positions [16]. In
BoNT/A arginine hydroxamate complex structure, Arg hydro-
xamate occupies the S19 site. But Zn is chelated by the carbonyl
oxygen and the hydroxamate group. Also the direction of the
peptide N to C is reversed [30].
S29 site is formed by Arg363, Asn368 and Asp370, while S39
subsite is formed by Tyr251, Leu256, Val258, Tyr366, Phe369
and Asn388. P39-Thr200 OG makes a hydrogen bond with
Tyr251 OH. P49-Lys201 is exposed to the solvent region. In the
present crystal structure the side chain density for this residue is
weak probably due to high thermal factors (Figures 1C and 1D).
However, one of the rotamer positions could form a hydrogen
bond with Gln162 OE1. This does not form a hydrogen bond in
the complex structure of BoNT/A-SNAP-25 (146–206) (PDB
id=1XTG). Instead Glu257 is close by, about 4.5A ˚.S 5 9 site is
made of Tyr251, Phe369, Leu256, Ser254 and Phe 423. P59-
Met202 occupies this hydrophobic pocket (Figure 4C).
Comparison of SNAP-25(146–206) and QRATKM at the
active site
The crystal structure of SNAP-25 (146–206) peptide with an
inactive double mutant (Pdb id=1XTG) had identified the
exosites as recognition sites distant from the active site [14].
However, the region of SNAP-25 peptide near the active site was
disordered and could not be modeled very well. Comparison of the
C-alpha position of the corresponding residues in the present
structure shows that the C-alpha positions of these six residues are
shifted. C-alphas of 197, 198, 199, 200, 201 and 202 are 4.34,
3.84, 3.55, 3.13, 5.69 and 6.12A ˚ for the corresponding C-alphas in
the present structures (Figure 5A). In the absence of Tyr366,
SNAP25 residues near the active site move towards 250 loop
increasing the distance from catalytic zinc. When the wild type
light chain is used, the SNAP peptide is closer to the catalytic zinc
and the 170 loop. This shift is probably due to either the disorder
or the inactive mutant in 1XTG. One possibility is that since
residues corresponding to a-exosites are missing in the short
peptide, the whole peptide could have slid down. But this
possibility is less likely since the b-exosite interaction is maintained
in both the structures. Though the C-alpha atom of P59 in the
current structure and 1XTG are farther apart, the side chains
occupy the same place. We conclude that this shift is due to the
loss of interaction of SNAP-25 with Tyr366 which has been
mutated to Phe in 1XTG. Because of this difference, P49-Lys201
has potential interaction with Gln162 of the enzyme rather than
Glu257. The length of the anti-parallel b sheet formed near the
250 loop (b-exosite) in 1XTG (13 A ˚) is almost double the length as
in QRATKM (6.5 A ˚) (Figure 5A). Based on the above
Figure 2. Binding of the substrate peptide in the active site of
Balc424. (A) Figure shows the substrate peptide (QRATKM) binding in
the active site of Balc424. Balc424 is shown in solid blue-colored surface.
Substrate peptide is shown in sphere (CPK) model. Carbon, oxygen,
nitrogen, sulfur and zinc atoms are shown in green, red, blue, yellow
and magenta, respectively. (B). Superposed stick models of QRATKM
and RRATKM are shown in green, and gray, respectively. Carbon atoms
are shown in green (QRATKM) and gray (RRATKM). Balc424 is shown in
semi-transparent surface (blue) representation with secondary elements
at the active site pocket. Only a few substrate-binding residues are
shown as markers. Pymol (DeLano, W.L. The PyMOL Molecular Graphics
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represent the substrate-enzyme complex interactions.
Though the overall conformation of the enzyme in 1XTG and the
current structure is very similar (RMSD is ,1A ˚ for 400 Ca atoms),
loops 200 and 250 vary significantly (Figure 5B). This conformational
change may be either due to the recognition of a-exositesin1XTGor
just an artifact of crystal packing. In the current structure, loops 200,
250 and 370 pack together tightly whereas in the 1XTG, 200 loop
moved away. The C-alphas of Pro206 (within 200 loop) in 1XTG
and QRATKM complex are ,12 A ˚ apart.
Comparison of QRATKM with N-Ac-CRATKML
Recently, the structure of a complex between the BoNT/A-LC
and an inhibitory peptide N-Ac-CRATKML has been reported
[31]. Though the direction of the polypeptide is the same, the
inhibitory peptide (N-Ac-CRATKML) is shifted down by one
residue compared to the substrate peptide QRATKM (Figure 5C).
This appears to be due to the effect of oxidation of Cys and the N-
terminal blocking acetyl group. The cysteine is oxidized to sulfenic
form. Both the sulfur and the OH group chelate the zinc ion unlike
in QRATKM complex where the carbonyl oxygen and amino
nitrogen of P1 residue chelate zinc (Figure 5D). As a consequence,
the acetyl group takes the C-alpha position of P19 (Arg198) and
P19 arginine moves to P29 alanine’s place. Moreover, P1 carbonyl
oxygen interacts with Arg363 instead of Tyr366. In QRATKM,
P1’ arginine forms salt bridge with Asp370 through guanidinium:-
carboxylate pair whereas in the N-Ac-CRATKML it is through a
single NE and OD1 interaction. Interestingly, even though the C-
alpha position has moved, Arg198 side chain takes a different
rotamer position made possible by the size of the cavity and stays
in the same pocket. In addition, P4’ lysine interacts with Tyr366
while in the substrate peptide (QRATKM) it interacts with
Figure 3. Structure of Balc424 in complex with the QRATKM, a segment of substrate SNAP-25. (A). Stereo view of the active site shows
the molecular interactions between the substrate peptide (QRATKM) and protease (Balc424). Protease and substrate residues are shown in cyan and
green, respectively. Blue color ribbon represents the protease secondary elements at the vicinity of the active site. (B). Stereo view of the active site
center of Balc424 (cyan stick) with RRATKM (gray ball and stick). Oxygen, nitrogen, sulfur and zinc atoms are shown in red, blue, yellow and magenta,
respectively. Hydrogen bonds are depicted as black dash lines while zinc co-ordination is shown in solid line.
doi:10.1371/journal.ppat.1000165.g003
Neurotoxin-Substrate Complex
PLoS Pathogens | www.plospathogens.org 5 September 2008 | Volume 4 | Issue 9 | e1000165Neurotoxin-Substrate Complex
PLoS Pathogens | www.plospathogens.org 6 September 2008 | Volume 4 | Issue 9 | e1000165Glu162. Hence the positioning of the inhibitory peptide (N-Ac-
CRATKML) may not represent the substrate binding position as
in QRATKM structure. In both cases the enzyme does not
undergo significant conformational changes as it did in the
structure of SNAP-25 (146–206) peptide complex [14].
Roles of substrate amino acid residues spanning the
cleavage site
N-Ac-CRATKML is a fairly good inhibitor (Ki 1.9 mM) [28].
But when the N terminal Cys is replaced with 2-mercapto-3-
phenylpropionyl (mpp) the Ki improved to 300nM. Keeping this as
a control various truncations were done [27]. Truncating the last
three residues of the mpp derivative (KML) increased the Ki 100-
fold while deletion of only the last two increased it only by ,13-
fold. The importance of Lys201 of the substrate may be attributed
to the potential hydrogen bond the terminal side chain atom (NZ)
makes with Gln162. Mutation of Lys201 to Ala increased the Ki
10 fold suggesting that the Lys side chain interaction is crucial.
When Thr200 of the substrate was mutated to Ala, Ki increased
only marginally since the hydrogen bond with OG was lost.
However, it is not clear from the present structure why Ala199Val
will increase the Ki ,10 fold. A simple modeling shows that the
S2’ subsite is big enough to accommodate a Val. Mutation of
Arg198 to Lys increases Ki by more than 1000 fold. This is
because both the salt bridge and stacking interactions are lost. It
appears stacking may be important since ionic interaction between
Lys201 and Asp370 is still possible. Though the present
hexapeptide lacks Leu203, truncation of this peptide had no effect
on Ki.
Recognition and binding of substrate by Balc424
Saturation mutation studies based on the crystal structure of
BoNT/A with SNAP-25 (146–206) has been used to define two
regions, active site (AS) domain and binding site (B) domain in
SNAP-25 [14; 29]. SNAP-25 residues 193–202 form AS while
residues 156–181 form B. Our hexapeptides form part of AS only.
In the same work, two minimal length peptides have been tested





201 (SN/A2) (the numbers correspond to our
numbering scheme). While SN/A1 was cleavable by BoNT/A,
SN/A2 was not, suggesting that the N terminal DEAN is required
for cleavage. This probably explains why QRATKM which lacks
DEAN was not cleaved in our case even though we used up to
1:30 ratio of Balc424 to peptide. However, the major reason for
the peptide not being cleaved is the amino group chelating zinc.
Any extension beyond in the N terminal direction would change
the character of this amino group and may not be able to chelate
zinc. However, the earlier study used GST fusion protein to
express the short peptide and might have some effect in binding to




th the activity compared to wild type
[22] and the mutants A195C and N196C in the 17-mer SNAP-25
substrate peptide [28] insignificantly affected Km and kcat.
The current structure confirms our earlier model for catalytic
mechanism [16]. Glu224 acts as the general base in abstracting a
proton from the nucleophilic water and also helps in shuttling
protons to the leaving group. In addition, the roles of Arg363 and
Tyr366 are to stabilize the substrate for proper positioning and
orientation as the carbonyl oxygens of P1 and P1’ are hydrogen
bonded to Tyr366 and Arg363. Tyr366 further stabilizes the
oxyanion role of P1 carbonyl oxygen. Another molecular
mechanism for BoNT/A recognition and cleavage of SNAP-25
has been proposed [29]. In that mechanism P5 (Asp193) residue of
SNAP25 is supposed to make the initial contact with the enzyme at
the a-exosites by forming a salt bridge with Arg177. This in turn
aligns P4’-Lys201 to form a salt bridge with Glu257. These
interactions are supposed to broaden the active site and allow P1’-
Arg198 to dock into the S1’ site by both electrostatic and
hydrophobic interactions. The current structure does not support
such a mechanism. First, the substrate peptide is able to dock into
S1’ site even though the peptide lacks substrate residues upstream
of P1. Second, the S1’ site of Balc424 with and without bound
peptide is similar and there is no indication of any change in shape
or size. Third, there is no possibility for Lys201 to make hydrogen
bond contact with Glu257. Accordingly, our crystallographic data
show that Balc424 is well positioned for peptide binding and
catalytic action without having to undergo a conformational
change. However, the interaction of P4’ with S4’ substrate may be
disrupted after cleavage and help the substrate to leave allowing
uncleaved peptide to bind in its place. But there is no experimental
or mutational evidence for that.
Implication for drug design
Even though botulinum neurotoxins are declared category A
biowarfare agents, effective drugs are yet to be developed.
Antibody therapeutics is emerging but more than one antibody
may be needed to contain the effect of a single serotype [32]. An
equine antitoxin is also available for post exposure therapeutics.
Small molecule inhibitors are being developed but the active site of
botulinum neurotoxin is large and it would be better to have larger
molecules or strongly binding peptidomimetic inhibitors to block
the active site. The current structure where S1 to S5’ sites have
been mapped unequivocally will be a good starting point. This
would at least give a serotype specific inhibitor that could be
transformed into an effective drug for botulinum neurotoxin A.
We have shown that the P1 residue could be changed to Arg
without affecting the binding efficiency and in fact it has proved to
be a better inhibitor since it complements the charge in that
region. It is known that changing it to cysteine improves binding
[27]. However, oxidation of Cys may cause a problem. The
structural environment of P1 also suggests that an amino acid
containing an aromatic ring may be better suited as it would
improve stacking interactions. The hexapeptide could be extended
by one residue at the N terminus. However, it might affect the
chelation of zinc by P1 amino group. The requirement of P1’ Arg
is crucial for BoNT/A activity. However, changing it to Tyr will
still keep the stacking interaction though the salt bridge would be
lost. Arg198Ala abolishes the activity without affecting the Km
value [33]. S2’ site also suggests that it can tolerate bigger
hydrophobic, aromatic residue. It is possible to introduce
modifications in the peptides to bring rigidity, specificity and
resistance from proteases. There are endless possibilities that can
Figure 4. Schematic diagram of the molecular interactions between the Balc424 and substrate peptides. The interactions between
Balc424 active site residues and the substrate peptides are shown. (A) QRATKM and (B) RRATKM. Black, red, blue, and yellow colored circles represent
carbon, oxygen, nitrogen, and sulfur atoms, respectively. For clarity, zinc co-ordination and water molecules involved in the interactions at the active
site are not shown. (C). A Schematic diagram representing S1 to S59sites. Residues of the enzyme forming the subsites and substrate peptide are
shown in red and blue, respectively. Proteolytic site is shown in cyan colored double-headed arrow. Figures A and B were prepared with Ligplot [37].
ChemDraw ultra (CambridgeSoft, Inc) was used to prepare figure C.
doi:10.1371/journal.ppat.1000165.g004
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biochemical assays with full length and truncated balc (balc424) do
not show much variation and hence the results are equally
applicable to both. It is desirable to have a broad spectrum
inhibitor to be effective across the serotypes and this structure will
be a starting point.
Figure 5. Comparison of Balc424 complexed with segments of SNAP-25 (197–202) and (146–204) and an inhibitor (N-Ac-CRATKML).
(A) and (B) show the superposition of Balc424 with SNAP-25 (197–202) and (146–204). Green and red represent SNAP-25 (197–202) and SNAP-25
(146–204), respectively. Superposition of Balc424 with substrate peptide (SNAP-25 [197–202]) and N-Ac-CRATKML peptide at the vicinity of the active




PLoS Pathogens | www.plospathogens.org 8 September 2008 | Volume 4 | Issue 9 | e1000165Acknowledgments
We gratefully acknowledge data collection support from beamline X29
(NSLS).
Author Contributions
Conceived and designed the experiments: SS. Performed the experiments:
DK RR. Analyzed the data: DK RR SAA SS. Contributed reagents/
materials/analysis tools: SAA. Wrote the paper: DK SS.
References
1. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC (1998) Crystal
structure of botulinum neurotoxin type A and implications for toxicity. Nat
Struct Biol 5(10): 898–902.
2. Simpson LL (1986) Molecular pharmacology of botulinum toxin and tetanus
toxin. Annu Rev Pharmacol Toxicol 26: 427–453.
3. Swaminathan S, Eswaramoorthy S (2000) Structural analysis of the catalytic and
binding sites of Clostridium botulinum neurotoxin B. Nat Struct Biol 7(8):
693–699.
4. DasGupta BR, Rasmussen S (1983) Amino acid composition of Clostridium
botulinum type F neurotoxin. Toxicon 21(4): 566–569.
5. DasGupta BR, Rasmussen S (1983) Purification and amino acid composition of
type E botulinum neurotoxin. Toxicon 21(4): 535–545.
6. Sathyamoorthy V, DasGupta BR (1985) Separation, purification, partial
characterization and comparison of the heavy and light chains of botulinum
neurotoxin types A, B, and E. J Biol Chem 260(19): 10461–10466.
7. Sathyamoorthy V, DasGupta BR (1985) Partial amino acid sequences of the
heavy and light chains of botulinum neurotoxin type E. Biochem Biophys Res
Commun 127(3): 768–772.
8. Menestrina G, Schiavo G, Montecucco C (1994) Molecular mechanisms of
action of bacterial protein toxins. Mol Aspects Med 15(2): 79–193.
9. Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum
neurotoxins. Mol Microbiol 13(1): 1–8.
10. Montecucco C, Schiavo G, Tugnoli V, de Grandis D (1996) Botulinum
neurotoxins: mechanism of action and therapeutic applications. Mol Med Today
2(10): 418–424.
11. Oguma K, Fujinaga Y, Inoue K (1995) Structure and function of Clostridium
botulinum toxins. Microbiol Immunol 39(3): 161–168.
12. Simpson LL (2000) Identification of the characteristics that underlie botulinum
toxin potency: Implications for designing novel drugs. Biochemie 82: 943–953.
13. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting
neuroexocytosis. Physiol Rev 80(2): 717–766.
14. Breidenbach MA, Brunger AT (2004) Substrate recognition strategy for
botulinum neurotoxin serotype A. Nature 432(7019): 925–929.
15. Sobel J (2005) Botulism. Clin Infect Dis 41(8): 1167–1173.
16. Kumaran D, Rawat R, Ludivico ML, Ahmed SA, Swaminathan S (2008)
Structure and substrate based inhibitor design for clostridium botulinum
neurotoxin serotype A. J Biol Chem 283: 18883–18891.
17. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in
oscillation mode. Methods Enzymol 276: 307–326.
18. Jones TA, Zou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for
building protein models in electron density maps and the location of errors in
these models. Acta Crystallogr A 47 (Pt 2): 110–119.
19. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998)
Crystallography & NMR system: A new software suite for macromolecular
structure determination. Acta Crystallogr D Biol Crystallogr 54(Pt 5): 905–921.
20. Laskowski RA (2001) PDBsum: summaries and analyses of PDB structures.
Nucleic Acids Res 29(1): 221–222.
21. Rawat R, Ashraf Ahmed S, Swaminathan S (2008) High level expression of the
light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to
monitor its proteolytic activity. Protein Expr Purif 60: 165–169.
22. Schmidt JJ, Bostian KA (1995) Proteolysis of synthetic peptides by type A
botulinum neurotoxin. J Protein Chem 14(8): 703–708.
23. Ahmed SA, Olson MA, Ludivico ML, Gilsdorf J, Smith LA (2008) Identification
of Residues Surrounding the Active Site of Type A Botulinum Neurotoxin
Important for Substrate Recognition and Catalytic Activity. Protein J.
24. Binz T, Bade S, Rummel A, Kollewe A, Alves J (2002) Arg(362) and Tyr(365) of
the botulinum neurotoxin type a light chain are involved in transition state
stabilization. Biochemistry 41(6): 1717–1723.
25. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, et al. (2007)
Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide
binding mode to a small molecule that is active in primary neurons. J Biol Chem
282(7): 5004–5014.
26. Schmidt JJ, Bostian KA (1997) Endoproteinase activity of type A botulinum
neurotoxin: substrate requirements and activation by serum albumin. J Protein
Chem 16(1): 19–26.
27. Schmidt JJ, Stafford RG (2002) A high-affinity competitive inhibitor of type A
botulinum neurotoxin protease activity. FEBS Lett 532(3): 423–426.
28. Schmidt JJ, Stafford RG, Bostian KA (1998) Type A botulinum neurotoxin
proteolytic activity: development of competitive inhibitors and implications for
substrate specificity at the S1’ binding subsite. FEBS Lett 435(1): 61–64.
29. Chen S, Kim JJ, Barbieri JT (2007) Mechanism of substrate recognition by
botulinum neurotoxin serotype A. J Biol Chem 282(13): 9621–9627.
30. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, et al. (2007)
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain
complexed with small-molecule inhibitors highlight active-site flexibility. Chem
Biol 14(5): 533–542.
31. Silvaggi NR, Wilson D, Tzipori S, Allen KN (2008) Catalytic Features of the
Botulinum Neurotoxin A Light Chain Revealed by High Resolution Structure of
an Inhibitory Peptide Complex. Biochemistry 47: 5736–5745.
32. Marks JD (2004) Deciphering antibody properties that lead to potent botulinum
neurotoxin neutralization. Mov Disord 19 Suppl 8: S101–108.
33. Chen S, Barbieri JT (2006) Unique substrate recognition by botulinum
neurotoxins serotypes A and E. J Biol Chem 281(16): 10906–10911.
34. Esnouf RM (1997) An extensively modified version of MolScript that includes
greatly enhanced coloring capabilities. J Mol Graph Model 15(2): 132–134,
112–133.
35. Esnouf RM (1999) Further additions to MolScript version 1.4, including reading
and contouring of electron-density maps. Acta Crystallogr D Biol Crystallogr
55(Pt 4): 938–940.
36. Merritt EA, Murphy ME (1994) Raster3D Version 2.0. A program for
photorealistic molecular graphics. Acta Crystallogr D Biol Crystallogr 50(Pt 6):
869–873.
37. Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: A program to
generate schematic diagrams of protein-ligand interactions. Prot Eng 8:
127–134.
Neurotoxin-Substrate Complex
PLoS Pathogens | www.plospathogens.org 9 September 2008 | Volume 4 | Issue 9 | e1000165